STAMPEDE: Systemic Therapy for Advancing or Metastatic Prostate Cancer--a multi-arm multi-stage randomised controlled trial.
Authors
James, Nicholas DSydes, Matthew R
Clarke, Noel W
Mason, Malcolm D
Dearnaley, David P
Anderson, John
Popert, Richard J
Sanders, Karen
Morgan, Rachel C
Stansfeld, J
Dwyer, John
Masters, John
Parmar, Mahesh K B
Issue Date
2008-10
Metadata
Show full item recordCitation
STAMPEDE: Systemic Therapy for Advancing or Metastatic Prostate Cancer--a multi-arm multi-stage randomised controlled trial. 2008, 20 (8):577-81 Clin OncolJournal
Clinical OncologyDOI
10.1016/j.clon.2008.07.002PubMed ID
18760574Type
ArticleLanguage
enISSN
0936-6555ae974a485f413a2113503eed53cd6c53
10.1016/j.clon.2008.07.002
Scopus Count
Related articles
- Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial.
- Authors: James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Anderson J, Popert RJ, Sanders K, Morgan RC, Stansfeld J, Dwyer J, Masters J, Parmar MK
- Issue date: 2009 Feb
- Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial.
- Authors: Sydes MR, Parmar MK, James ND, Clarke NW, Dearnaley DP, Mason MD, Morgan RC, Sanders K, Royston P
- Issue date: 2009 Jun 11
- Phase II trial of weekly Docetaxel, Zoledronic acid, and Celecoxib for castration-resistant prostate cancer.
- Authors: Kattan J, Bachour M, Farhat F, El Rassy E, Assi T, Ghosn M
- Issue date: 2016 Aug
- Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial.
- Authors: James ND, Sydes MR, Mason MD, Clarke NW, Anderson J, Dearnaley DP, Dwyer J, Jovic G, Ritchie AW, Russell JM, Sanders K, Thalmann GN, Bertelli G, Birtle AJ, O'Sullivan JM, Protheroe A, Sheehan D, Srihari N, Parmar MK, STAMPEDE investigators
- Issue date: 2012 May
- Is There a Benefit of Addition Docetaxel, Abiraterone, Celecoxib, or Zoledronic Acid in Initial Treatments for Patients Older Than 70 Years With Hormone-sensitive Advanced Prostate Cancer? A Meta-analysis.
- Authors: Landre T, Guetz GD, Chouahnia K, Fossey-Diaz V, Taleb C, Culine S
- Issue date: 2019 Aug